@article{e46318b8d01a42dbac2bb07e209efb8e,
title = "Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report",
abstract = "Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes-modifying therapies in children will enable industry, academia, funders, advocacy groups, and regulators to translate new science to clinical care. This consensus report characterizes the fundamental differences in type 1 diabetes between children and adults and proposes a thoughtful approach to better understand the development and regulatory pathways for type 1 diabetes therapies.",
author = "Wherrett, {Diane K.} and Chiang, {Jane L.} and Delamater, {Alan M.} and Dimeglio, {Linda A.} and Gitelman, {Stephen E.} and Gottlieb, {Peter A.} and Herold, {Kevan C.} and Lovell, {Daniel J.} and Orchard, {Trevor J.} and Ryan, {Christopher M.} and Schatz, {Desmond A.} and Wendler, {David S.} and Greenbaum, {Carla J.}",
note = "Funding Information: Funding and Duality of Interest. All authors have completed the Unified Competing Interest form at www.icmje.org/conflicts-of-interest (available upon request from J.L.C.) and declare the following conflicts of interest. L.A.D. reports personal fees from Sanofi and grants from Novo Nordisk, outside the submitted work. P.A.G. reports grants from Pfizer, JDRF, Novartis, the NIH, and Omni Bio Pharmaceutical and nonfinancial support from ViaCyte, Genentech, and Baxter, outside the submitted work. P.A.G. has a patent related to the use of AAT for the treatment of type 1 diabetes with royalties paid to Omni Bio Pharmaceutical. D.J.L. reports grants from Bristol-Myers Squibb and other support from AstraZeneca, Bristol-Myers Squibb, AbbVie, Pfizer, Roche, Novartis, UBC, Forest Laboratories, Horizon Pharma, Johnson & Johnson, Biogen, Takeda, Genentech, GlaxoSmithKline, Boehringer Ingelheim, and Celgene, outside the submitted work. T.J.O. reports grants from the National Institute of Diabetes and Digestive and Kidney Diseases, during the conduct of the study; personal fees from the Profil Institute for Clinical Research, Eli Lilly, Abbott Laboratories, and Gilead; and other support from Bristol-Myers Squibb, outside the submitted work. C.M.R. reports personal fees from Novo Nordisk, outside the submitted work. C.J.G. reports grants from Novo Nordisk and Novartis, outside the submitted work. No other potential conflicts of interest relevant to this article were reported. Publisher Copyright: {\textcopyright} 2015 by the American Diabetes Association.",
year = "2015",
month = oct,
doi = "10.2337/dc15-1429",
language = "English (US)",
volume = "38",
pages = "1975--1985",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "10",
}